What is HC Wainwright’s Forecast for RYTM FY2027 Earnings?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) – Research analysts at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Rhythm Pharmaceuticals in a research note issued to investors on Monday, March 2nd. HC Wainwright analyst R. Selvaraju expects that the company will post earnings per share of $1.06 for the year. HC Wainwright has a “Buy” rating and a $110.00 price target on the stock. The consensus estimate for Rhythm Pharmaceuticals’ current full-year earnings is ($4.32) per share.

Several other research firms have also recently weighed in on RYTM. Citigroup restated an “outperform” rating on shares of Rhythm Pharmaceuticals in a research report on Friday, December 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 22nd. Morgan Stanley reaffirmed an “overweight” rating and set a $150.00 price objective on shares of Rhythm Pharmaceuticals in a report on Thursday, December 11th. Canaccord Genuity Group lowered their target price on Rhythm Pharmaceuticals from $141.00 to $140.00 and set a “buy” rating for the company in a research note on Monday. Finally, Wall Street Zen lowered Rhythm Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $132.07.

Rhythm Pharmaceuticals Stock Up 1.6%

Rhythm Pharmaceuticals stock opened at $91.00 on Tuesday. The stock has a 50-day simple moving average of $102.65 and a 200 day simple moving average of $103.42. The stock has a market capitalization of $6.21 billion, a price-to-earnings ratio of -29.26 and a beta of 2.06. Rhythm Pharmaceuticals has a 12-month low of $45.90 and a 12-month high of $122.20.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last posted its quarterly earnings data on Thursday, February 26th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.79) by $0.06. Rhythm Pharmaceuticals had a negative return on equity of 266.56% and a negative net margin of 103.57%.The company had revenue of $57.25 million for the quarter, compared to analyst estimates of $56.16 million. During the same quarter in the previous year, the firm earned ($0.72) earnings per share. The business’s revenue was up 36.9% on a year-over-year basis.

Institutional Trading of Rhythm Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Xponance LLC boosted its stake in Rhythm Pharmaceuticals by 2.6% during the 4th quarter. Xponance LLC now owns 4,269 shares of the company’s stock worth $457,000 after acquiring an additional 107 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its holdings in Rhythm Pharmaceuticals by 4.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,568 shares of the company’s stock worth $259,000 after purchasing an additional 110 shares during the period. Smartleaf Asset Management LLC boosted its position in shares of Rhythm Pharmaceuticals by 39.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 399 shares of the company’s stock worth $43,000 after purchasing an additional 113 shares in the last quarter. Captrust Financial Advisors increased its position in shares of Rhythm Pharmaceuticals by 0.7% in the 2nd quarter. Captrust Financial Advisors now owns 17,471 shares of the company’s stock valued at $1,104,000 after buying an additional 114 shares in the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Rhythm Pharmaceuticals by 48.6% in the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock valued at $39,000 after buying an additional 118 shares in the last quarter.

Insiders Place Their Bets

In related news, CFO Hunter C. Smith sold 4,385 shares of the company’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $101.26, for a total value of $444,025.10. Following the completion of the sale, the chief financial officer owned 110,512 shares in the company, valued at approximately $11,190,445.12. This represents a 3.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Pamela J. Cramer sold 3,350 shares of the stock in a transaction dated Thursday, December 11th. The shares were sold at an average price of $111.00, for a total value of $371,850.00. Following the completion of the transaction, the insider directly owned 20,814 shares in the company, valued at $2,310,354. The trade was a 13.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 25,003 shares of company stock worth $2,589,015. 6.10% of the stock is currently owned by company insiders.

Key Stories Impacting Rhythm Pharmaceuticals

Here are the key news stories impacting Rhythm Pharmaceuticals this week:

• Positive Sentiment: Canaccord Genuity raised its price target to $140, signaling stronger upside expectations from that shop and likely supporting buying interest. Canaccord raises PT to $140
• Neutral Sentiment: H.C. Wainwright reaffirmed a “Buy” stance and set a $110 target, keeping institutional support for the stock even after adjusting assumptions; that helps sentiment but is less bullish than Canaccord’s view. H.C. Wainwright price target cut to $110
• Negative Sentiment: H.C. Wainwright cut near-term EPS forecasts sharply — trimming FY2026 and multiple quarterly estimates and pushing meaningful profitability into 2027 (they still model positive EPS in FY2027). Those downgraded near-term earnings projections increase execution risk and explain some downward pressure/volatility despite the maintained Buy rating.

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals, Inc is a clinical‐stage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortin‐4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.

The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.